Overview

Ranibizumab Treatment for Retinal Vein Occlusion

Status:
Unknown status

Trial end date:
2019-09-01

Target enrollment:

Participant gender:

Summary

In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment have not been evaluated comprehensively. Therefore, we have planned to analyze predictors for visual outcome from a viewpoint of electrophysiology and biomarkers besides morphological features by SD-OCT.

Phase:

N/A

Details

Lead Sponsor:

Kyoto University, Graduate School of Medicine

Collaborator:

Novartis

Treatments:

Ranibizumab